LobbyingAmerican Academy of Orthopaedic Surgeons lobbying by quarter
American Academy of Orthopaedic Surgeons's latest lobbying report covers Q2 2026, at $35K. The four quarters Q4 2025–Q3 2026 total $105K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Budget/Appropriations.
American Academy of Orthopaedic Surgeons
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $105K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $10.8K | 1 |
| Q1 2023 | $9,069 | 1 |
| Q2 2023 | $23.3K | 1 |
| Q3 2023 | $64.4K | 1 |
| Q4 2023 | $19.7K | 1 |
| Q1 2024 | $24.3K | 1 |
| Q2 2024 | $17.1K | 1 |
| Q3 2024 | $60.9K | 1 |
| Q4 2024 | $16K | 1 |
| Q1 2025 | $10K | 2 |
| Q2 2025 | $10K | 1 |
| Q3 2025 | $10K | 1 |
| Q4 2025 | $35K | 2 |
| Q1 2026 | $35K | 2 |
| Q2 2026 | $35K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$60K · 6 reports
- Budget and appropriations$37.5K · 3 reports
- Defense$37.5K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES9 reports
- SENATE9 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseAmerican Academy of Orthopaedic Surgeons | $245.6K | 10 quarters |
| SL Strategies | $75K | 3 quarters |
| Hart Health Strategies | $60K | 6 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| SARA LOVE RAWLINGS | U.S. Senate Committee on Appropriations | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/19for Q3 | Holland & Knight | Under $5,000 |
| 08/17for Q2 | SL Strategies | $25K |
| 07/20for Q2 | Hart Health Strategies | $10K |
| 05/04for Q1 | SL Strategies | $25K |
| 04/20for Q1 | Hart Health Strategies | $10K |
| 01/20for Q4 2025 | SL Strategies | $25K |
| 01/16for Q4 2025 | Hart Health Strategies | $10K |
| 25/10/23for Q4 2025 | SL Strategies | Under $5,000 |
| 25/10/20for Q3 2025 | Hart Health Strategies | $10K |
| 25/07/10for Q2 2025 | Hart Health Strategies | $10K |
| 25/04/22for Q1 2025 | In-house | Under $5,000 |
| 25/04/18for Q1 2025 | Hart Health Strategies | $10K |
| 25/01/17for Q4 2024 | In-house | $16K |
| 25/01/05for Q1 2025 | Hart Health Strategies | Under $5,000 |
| 24/10/18for Q3 2024 | In-house | $60.9K |
| 24/07/15for Q2 2024 | In-house | $17.1K |
| 24/04/19for Q1 2024 | In-house | $24.3K |
| 24/01/19for Q4 2023 | In-house | $19.7K |
| 23/10/18for Q3 2023 | In-house | $64.4K |
| 23/07/19for Q2 2023 | In-house | $23.3K |